In the specialized field of biochemical research, the par 4 peptide—specifically the PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2)—has become a cornerstone for investigators studying cellular signaling pathways. As someone who Nov 16, 2008 — The current report shows that PAR4 uses its anionic cluster to interact with α-thrombin and that this interaction is important even in the has followed the progression of peptide synthesis and its application in in vitro experimental models, I find the specificity of this tool particularly fascinating.
Understanding the Mechanism of Action
Proteinase-activated receptor 4 (PAR-4) is a unique member of the G-protein-coupled receptor (GPCR) family. Unlike many receptors that require complex binding interactions, PAR4 is effectively "tethered" and activated through a proteolytic cleavage event. My review of recent literature suggests that PAR4 can be activated either by the native protease thrombin cleavage event or by a synthetic soluble agonist peptide mimicking the tethered ligand.
The PAR-4 agonist peptide serves as a vital proxy in these studies. Specifically, the PAR-4 agonist peptide stimulates thromboxane production by human platelets, providing researchers with a controlled method to observe signaling cascades without the need for high concentrations of native thrombin. It is important to note that PAR4 requires ≈10-fold more thrombin for proteolysis compared to other receptors like PAR1, making the use of a synthetic PAR-4 Agonist Peptide, amide an essential requirement for precise, reproducible results.
Key Characteristics and Experimental Use
When conducting experiments, specificity is paramount. The Nov 16, 2008 — The current report shows that PAR4 uses its anionic cluster to interact with α-thrombin and that this interaction is important even in the PAR-4-AP (TFA) is a selective agonist for Proteinase-Activated Receptor 4 (PAR-4), showing no cross-reactivity with PAR-1 or PAR-2. This selectivity allows for the isolation of PAR4-mediated responses.
* AY-NH2 is a selective PAR4 receptor agonist peptide that has been widely validated in laboratory settings.
* The PAR4 specific agonist peptide, AYPGKF is another iteration often utilized for probing signaling pathways in culture systems.
* Evidence shows that the am A proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist. ino terminus of the fourth protease-activated receptor (PAR4) is effectively mimicked by these synthetic variants, which are readily activated both wild-type and mutant PAR4 receptors.
Physiological Context and Future Directions
The broader context of this research often touches on how PARs are activated by proteases generated during tissue damage. Because PAR4 plays a role in various cellular responses, it is highly relevant to studies involving inflammation and tissue repair.
Interestingly, PAR4 targeting is a safer strategy for preventing thrombosis, and many researchers are investigating how it provides robust antithrombotic activity with low bleeding profiles compared to traditional methods. Furthermore, there is emerging interest in the idea that PAR4 inhibition may mitigate thrombin-associated inflammation and neurovascular pathology.
As a Proteinase-activated receptor (PAR)-4 enthusiast, I have observed that PAR4 is a recently characterized thrombin receptor that continues to provide surprises. For those working with PAR4 (protease-activated receptor 4), the ability to utilize a PAR4 signal peptide in experimental designs has opened new doors for understanding how PAR4 uses its anionic cluster to interact with α-thrombin.
Observations on Specificity
It is worth noting that not all factors interact with these receptors in the same way. For instance, data indicates that complement factor C4a does not activate PAR1 or PAR4 on human platelets, which helps researchers further refine their focus on the specific ac An optimized agonist peptide of protease-activated tivation pathways of the PAR 4 system.
As PAR4 is an emerging target for anti-platelet drugs, the continued refinement of the par 4 peptide as a re PAR-4 Agonist Peptide, amide | CAS 352017-71-1 search tool remains a high priority. Whether you are using the PAR-4-AP in Protease-Activated Receptor-4, PAR-4 Agonist, amide a standard assay or exploring the nuances of 4-related signaling, the precision provided by these synthetic peptides is indispensable for modern molecular biology.
***
*Disclaimer: This art by X Han · 2021 · Cited by 8 — Complement factor C4a does not activate PAR1 or PAR4 on human platelets. These data show that PAR1 and PAR4 activation by C4a on microvascular cells likely icle is for informational purposes for research professionals and does not constitute medical advice or recommendations for human consumption. All materials discussed are intended strictly for laboratory and resea PAR4 (Protease-Activated Receptor 4) rch use.*